U.S. Marine and Shipping Stock News

NasdaqGS:ATEC
NasdaqGS:ATECMedical Equipment

Is Narrowing Losses And Reaffirmed 2026 Outlook Altering The Investment Case For Alphatec (ATEC)?

In late February 2026, Alphatec Holdings, Inc. reported that its fourth-quarter 2025 net loss narrowed to US$21.73 million and full-year net loss improved to US$143.36 million, while reaffirming its 2026 revenue outlook of about US$890 million. Management also highlighted strong surgeon adoption, double-digit surgical volume and revenue growth in 2025, and a goal to generate US$20 million in free cash flow in 2026, underscoring its focus on scaling an integrated spine surgery platform. With...
NYSE:FE
NYSE:FEElectric Utilities

The Bull Case For FirstEnergy (FE) Could Change Following 2025 Results And New US$36B Grid Plan

FirstEnergy Corp. has reported its 2025 results, with revenue rising to US$15.09 billion and net income reaching US$1.02 billion, alongside modestly higher earnings per share from continuing operations. At the same time, the company unveiled its Energize365 program, a US$36 billion capital plan for 2026–2030 that heavily prioritizes transmission upgrades and grid resilience, aiming to support long-term value creation. Next, we'll examine how this expanded US$36 billion Energize365 investment...
NYSE:PR
NYSE:PROil and Gas

Does Permian’s Q4 Beat And Dividend Hike Shift The Bull Case For Permian Resources (PR)?

In late February 2026, Permian Resources Corporation reported fourth‑quarter 2025 results showing higher production across oil, NGLs, and natural gas, alongside net income of US$339.51 million and quarterly diluted EPS of US$0.45. The company coupled record operational performance and an earnings beat with a 7% increase in its quarterly base dividend to US$0.16 per share, highlighting an emphasis on cost efficiency, acquisitions, and cash returns despite softer revenue. Next, we’ll examine...
NYSE:WTTR
NYSE:WTTREnergy Services

Select Water Solutions (WTTR) Is Up 7.4% After $175 Million Equity Raise For Water Infrastructure Expansion – Has The Bull Case Changed?

In February 2026, Select Water Solutions, Inc. completed a US$175.0 million follow-on offering of 13,725,491 Class A shares at US$12.75 each under a new universal shelf registration, adding to its previously authorized but unused 2024 buyback program and prior completed repurchases. The company has indicated that the fresh equity capital will support general corporate purposes, including expanding its water infrastructure portfolio, potential acquisitions, and possible debt reduction,...
NasdaqGS:LGIH
NasdaqGS:LGIHConsumer Durables

What Does LGI Homes' (LGIH) New Puyallup Community Reveal About Its High-Demand Market Strategy?

LGI Homes recently announced the past grand opening of Meadow Brook, a 53-home community in Puyallup, Washington, offering three- to five-bedroom single-family and duplex homes with its CompleteHome Plus package and convenient access to nearby Tacoma amenities. The project not only widens LGI Homes’ footprint in the greater Seattle area but also showcases its focus on move-in-ready, upgraded homes in supply-constrained, high-demand markets. We’ll now examine how this expansion of LGI Homes’...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

A Look At Dentsply Sirona (XRAY) Valuation After Q4 Beat And 24‑Month Turnaround Plan

Dentsply Sirona (XRAY) shares have been reacting to a mixed fourth quarter, with a revenue beat and year-on-year sales growth, paired with softer full-year guidance and a 24-month return-to-growth plan. See our latest analysis for DENTSPLY SIRONA. The mixed Q4 and impairment news has arrived alongside a sharp sentiment shift, with a 1 day share price return of 15.5% and a 90 day share price return of 31.31%, even though the 1 year total shareholder return is a 6.96% loss and the 5 year total...
NYSE:UI
NYSE:UICommunications

The Bull Case For Ubiquiti (UI) Could Change Following Zacks Rank Upgrade On Earnings Outlook

Ubiquiti Inc. was recently elevated to a Zacks Rank #1 (Strong Buy), reflecting upgraded earnings forecasts and a more favorable earnings outlook for the business. This shift in analyst rating highlights how improving earnings expectations can reshape perceptions of Ubiquiti’s core operations and overall investment profile. Next, we will examine how this improved earnings outlook and Zacks upgrade shape Ubiquiti’s broader investment narrative for investors. Uncover the next big thing with 30...
NYSE:KGS
NYSE:KGSEnergy Services

Why Kodiak Gas Services (KGS) Is Up 7.8% After Record 2025 Results And Power Push

Kodiak Gas Services recently reported fourth-quarter 2025 revenue of US$332.87 million and net income of US$24.63 million, capping a record full year with US$1.31 billion in revenue and US$80.52 million in net income. The company paired this strong performance with a US$6.34 million long-lived asset impairment and the announcement of an expansion into power generation through acquiring Distributed Power Solutions, supported by technology-driven efficiency gains and higher dividends. We’ll...
NYSE:ROG
NYSE:ROGElectronic

How Investors Are Reacting To Rogers (ROG) Net Loss, Softer Sales And Completed Buyback Program

In February 2026, Rogers Corporation reported full-year 2025 results showing sales of US$810.8 million versus US$830.1 million a year earlier and a net loss of US$61.8 million, alongside first-quarter 2026 sales guidance of US$193 million to US$208 million. The company also disclosed that it has completed a long-running buyback program, repurchasing 2,120,103 shares, or 11.48% of its share count, for US$147.44 million since 2015, which may influence how investors weigh recent losses against...
NYSE:SILA
NYSE:SILAHealth Care REITs

How Investors Are Reacting To Sila Realty Trust (SILA) Softer Earnings And Steady US$0.40 Dividend

Sila Realty Trust, Inc. reported past fourth-quarter and full-year 2025 results showing higher revenue of US$50.7 million for the quarter and US$197.54 million for the year, but lower net income of US$5.02 million and US$33.12 million respectively, while funds from operations reached US$30.4 million in Q4 and US$120.9 million for 2025. Alongside these earnings, the board approved a US$0.40 per-share quarterly dividend and highlighted high occupancy, strong lease retention, and active...
NYSE:TR
NYSE:TRFood

Did Stronger 2025 Results and a Steady Dividend Just Shift Tootsie Roll Industries' (TR) Investment Narrative?

Tootsie Roll Industries, Inc. has reported its full-year 2025 results, with sales of US$7.85 million, revenue of US$732.52 million, and net income of US$100.05 million, while also affirming a quarterly dividend of US$0.09 per share payable on March 27, 2026. The increase in both revenue and net income, alongside higher basic earnings per share from continuing operations, points to improved profitability and operating efficiency. We’ll explore how this earnings growth and dividend affirmation...
NYSE:CTEV
NYSE:CTEVHealthcare Services

Claritev (CTEV) Is Down 42.1% After Launching $75 Million Buyback Amid Ongoing Losses - What's Changed

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...
NasdaqGS:PRDO
NasdaqGS:PRDOConsumer Services

Assessing Perdoceo Education’s (PRDO) Valuation After Earnings Growth Guidance And Dividend Affirmation

Perdoceo Education (PRDO) drew fresh attention after reporting fourth quarter and full year 2025 earnings, issuing new 2026 guidance, and affirming its quarterly dividend, giving investors several data points to reassess the stock. See our latest analysis for Perdoceo Education. The recent earnings, 2026 guidance and dividend affirmation come after a period of steady share price strength, with a 90 day share price return of 19.83% and a 1 year total shareholder return of 32.10% supporting a...
NasdaqGM:WLDN
NasdaqGM:WLDNProfessional Services

A Look At Willdan Group (WLDN) Valuation After Record Results And New US$49 Million Energy Contract

Willdan Group (WLDN) is back in focus after reporting higher fourth quarter and full year revenue and net income, alongside a new US$49 million energy services contract with Mt. San Antonio College in California. See our latest analysis for Willdan Group. Despite the strong contract wins and record financial results, Willdan Group’s share price has seen a sharp pullback recently, with a 1 day share price return of negative 25.47% and a 30 day share price return of negative 29.37%. At the same...
NYSE:UCB
NYSE:UCBBanks

Assessing Whether United Community Banks (UCB) Still Looks Undervalued After Recent Share Price Weakness

Without a specific news announcement driving attention today, United Community Banks (UCB) still offers investors concrete data points to consider, including recent share performance, profitability metrics, and value-focused scores. See our latest analysis for United Community Banks. At a share price of $32.17, United Community Banks has seen a 6.56% 1 month share price decline, while its 90 day share price return of 3.91% and 1 year total shareholder return of 3.10% point to relatively...
NYSE:PIPR
NYSE:PIPRCapital Markets

Is Piper Sandler (PIPR) Quietly Recasting Its Healthcare Brand Around High-Margin Advisory Niches?

Piper Sandler Companies recently expanded its healthcare investment banking franchise, appointing Jason Arnold as a managing director focused on life science tools and diagnostics and naming Aamer Naseer global head of life sciences outsourcing and B2B med tech. These hires deepen Piper Sandler’s sector expertise at a time when life sciences outsourcing and diagnostics are increasingly central to healthcare deal and capital-raising activity. We’ll now examine how this refreshed life sciences...
NYSE:GKOS
NYSE:GKOSMedical Equipment

Glaukos (GKOS) Valuation Check As iDose Sales Momentum Meets Impairment Charge And Upbeat 2026 Outlook

Glaukos (GKOS) is back in focus after its fourth quarter 2025 report paired strong sales figures with a sizeable impairment charge, followed shortly by fresh 2026 sales guidance and a new ESOP related shelf registration. See our latest analysis for Glaukos. The recent impairment charge and ESOP related shelf registration come against a backdrop of steady share price gains, with a 90 day share price return of 13.28% and a very large 3 year total shareholder return of 139.03%. This suggests...
NasdaqGM:ALNT
NasdaqGM:ALNTElectrical

Assessing Allient (ALNT) Valuation As Operational Headwinds And Capital Choices Pressure Growth

Allient’s recent challenges come into focus Recent commentary on Allient (ALNT) has focused on two years of annual sales and earnings declines, alongside new share issuances and weaker returns on capital, raising fresh questions about how efficiently the business is being run. See our latest analysis for Allient. Allient’s recent share price has eased back, with a 1-day share price return of a 1.9% decline and a 7-day share price return of a 3.7% decline. However, the 90-day share price...
NasdaqGS:XERS
NasdaqGS:XERSPharmaceuticals

Xeris Biopharma Holdings (XERS) Is Down 7.4% After Suing to Block Recorlev Generics Until 2040

Xeris Biopharma recently filed a Hatch-Waxman patent infringement lawsuit in the US District Court for the District of New Jersey against Torrent Pharmaceuticals and Somerset Therapeutics, seeking to block generic versions of its Cushing’s syndrome therapy Recorlev until its patents expire in March 2040. This legal move highlights how central Recorlev’s intellectual property protection is to Xeris’s long-term product exclusivity and potential revenue longevity in its endocrine...
NYSE:SEE
NYSE:SEEPackaging

Assessing Sealed Air (SEE) Valuation As Shares Trade Near Recent Levels

Why Sealed Air is on investors’ radar today Sealed Air (SEE) is back in focus after recent trading left the shares around $41.88, prompting investors to reassess how its packaging business and current valuation line up with their expectations. See our latest analysis for Sealed Air. While the 1-day and 7-day share price returns are slightly negative, Sealed Air’s 1-year total shareholder return of 25.46% contrasts with weaker 3-year and modest 5-year total shareholder returns, which suggests...
NYSE:GEF
NYSE:GEFPackaging

Assessing Greif (GEF) Valuation As Mixed Near‑Term Returns Contrast With Longer‑Term Gains

Greif stock moves and recent performance snapshot Greif (GEF) has attracted fresh attention after a period of mixed short term returns, including a 0.1% one day slip and a 2.6% decline over the past week, alongside positive longer term performance. With the shares last closing at US$72.67 and total return figures of 3% over the past month and 9.4% over the past 3 months, investors are reassessing how this industrial packaging company fits into their portfolios. See our latest analysis for...
NYSE:RLI
NYSE:RLIInsurance

Will A++ Upgrade and New Debt Deal Change RLI's (RLI) Risk‑Reward Narrative for Investors?

In late February 2026, RLI Corp. completed a US$300 million fixed-rate senior unsecured bond offering of 5.375% Notes due June 1, 2036, following a new debt shelf registration and alongside a board decision to maintain its quarterly dividend at US$0.16 per share, extending a 50-year dividend increase streak. A recent AM Best upgrade of RLI Group’s financial strength rating to A++, coupled with an equity-backed partnership with AI-focused insurer Kettle to launch a new multi-peril commercial...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?

EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU’s target markets. We’ll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU’s commercialization may influence...
NYSE:XYL
NYSE:XYLMachinery

Will Xylem’s (XYL) New $1.5 Billion Buyback and Dividend Hike Change Its Capital Allocation Narrative?

On February 25, 2026, Xylem Inc. (NYSE: XYL) authorized a new US$1.50 billion share repurchase program with no expiration date, alongside an 8% increase in its quarterly dividend. The combination of a sizable buyback, higher dividend, and recent record profitability underlines management’s confidence in Xylem’s cash generation and balance sheet strength. We’ll now examine how Xylem’s sizeable new buyback authorization could reshape its investment narrative around capital allocation and...